Latest News

(UroToday.com)Cisplatin-based chemotherapy is associated with improved responses and more durable outcomes than carboplatin in mUC, though the mechanisms for this are poorly characterized. An exploratory subset analysis of the IMvigor130 trial suggested that the addition of atezolizumab to cisplatin-based chemotherapy had more efficacy (hazard ratio for overall survival 0.73 (0.54 – 0.98) with cisplatin versus […]

The time between diagnosis of organ-confined prostate cancer and definitive therapy with radical prostatectomy provides an interval for intervention, with the benefit of pre- (biopsy specimen) and post-intervention (surgical specimen) tissue for comparison. The authors of “Loss of SNAI2 in Prostate Cancer Correlates with Clinical Response to Androgen Deprivation Therapy” present molecular studies from their […]

Avelumab initially received regulatory approval for patients with metastatic urothelial carcinoma in the post-platinum chemotherapy setting based on an objective response rate of 16.5%.1  In the post-platinum chemotherapy setting, both nivolumab and pembrolizumab also currently retain their regulatory approval status.  However, the situation where avelumab has the strongest data is in the maintenance-switch setting.  I […]

Androgen receptor (AR) signaling is important in prostate cancer progression, and therapies that target this pathway have been the mainstay of treatment for advanced disease for over 70 years. Tumors eventually progress despite castration through a number of well-characterized mechanisms; however, little is known about what determines the magnitude of response to short-term pathway inhibition.

Testicular germ cell tumors (TGCTs) are the most common tumors in adolescent and young men. Recently, genome-wide studies have made it possible to progress in understanding the molecular mechanisms underlying the development of tumors.

To identify preoperative characteristics in patients with renal masses that influence operative time during robot-assisted partial nephrectomy (RAPN) and evaluate the relationship between operative time and length of stay, complication rates, and overall outcome.

Growing findings have demonstrated that interferon regulatory transcription factor (IRF) family members are linked to the progression of various cancers. However, the roles of IRFs in clear cell renal cell carcinoma (ccRCC) remain undefined.

The risk of prostate cancer among persons living with HIV (PWH) is not well understood and may be obscured by different opportunities for detection. We identified 123,472 (37,819 PWH and 85,653 comparators) men enrolled in the Veterans Aging Cohort Study, a prospective national cohort of PWH and demographically-matched, uninfected comparators in 2000-2015.

To assess whether sampling of the transitional-zone can be spared in patients with exclusively peripheral prostate cancer (PCa)-suspicious mpMRI lesions, who undergo combined mpMRI targeted (TBx) and systematic prostate biopsies (SBx).

To compare cancer specific mortality (CSM) rates between radical prostatectomy (RP) vs. external beam radiotherapy (EBRT) in National Comprehensive Cancer Network (NCCN) high risk (HR) patients, as well as in Johns Hopkins University (JH) high-risk (HR) and very high risk (VHR) subgroups.